Champiat and colleagues have identified in their trial participants a group of patients that appear to have accelerated tumor progression when treated with PD1/PDL1 inhibitors. While their work is provocative, there are several limitations present in their analysis. Investigators should work quickly to verify and better characterize these results.
- Received January 30, 2017.
- Accepted February 16, 2017.
- Copyright ©2017, American Association for Cancer Research.